Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Gains from Sales and Divestitures (2024 - 2025)

TransMedics (TMDX) has 2 years of Gains from Sales and Divestitures data on record, last reported at $1280.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 101.24% year-over-year to $1280.0; the TTM value through Dec 2025 reached $1280.0, up 101.24%, while the annual FY2025 figure was $1280.0, 101.24% up from the prior year.
  • Gains from Sales and Divestitures reached $1280.0 in Q4 2025 per TMDX's latest filing, down from $15157.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $111419.0 in Q1 2025 and bottomed at -$103372.0 in Q4 2024.